Fig. 1: Distributions of BD1 and of BD29 neutralizing antibody (nAb) and binding antibody (bAb) marker levels, stratified by Omicron COVID-19 case vs. non-case status and by SARS-CoV-2 naive vs. non-naive status.
From: Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
a–d nAb titer against Spike (BA.1 strain) pseudovirus; e–h IgG bAb concentration against Spike (BA.1 strain). Points are from per-protocol boosted participants in the original-vaccine (filled triangles) or crossover-vaccine (open circles) arm with lines (gray: original-vaccine arm; red: crossover-vaccine arm) connecting the BD1 and BD29 data points for an individual participant (a, e: n = 79; b, f: n = 84; c, g: 32; d, h: n = 23). The violin plots contain interior box plots with upper and lower horizontal edges representing the 25th and 75th percentiles of antibody level and middle line representing the 50th percentile. The vertical bars represent the distance from the 25th (or 75th) percentile of antibody level and the minimum (or maximum) antibody level within the 25th (or 75th) percentile of antibody level minus (or plus) 1.5 times the interquartile range. Each side shows a rotated probability density (estimated by a kernel density estimator with a default Gaussian kernel) of the data. Positive response rates were computed with inverse probability of sampling weighting. LLOQ, lower limit of quantification. AU/ml, arbitrary units/ml. LLOQ = 8 AU/ml for nAb BA.1 and 102 AU/ml for Spike IgG BA.1. Positive (quantifiable) response for BA.1 nAb at a given timepoint was defined by value ≥LLOQ at that timepoint. Positive response for Spike IgG-BA.1 bAb at a given timepoint was defined by value ≥LLOQ at that timepoint. Omicron Case = COVID-19 endpoint in the interval [≥7 days post BD29 AND ≥December 1, 2021 to April 5, 2022 (data cutoff date)]. Non-case = Did not acquire COVID-19 (of any strain) in the interval [BD1 to April 5, 2022]. SARS-CoV-2 naive = No evidence of SARS-CoV-2 infection from enrollment through to BD1; Non-naive = Any evidence of SARS-CoV-2 infection in the interval [≥14 days after the first two doses of mRNA-1273, BD1].
